US Patent:
20230014839, Jan 19, 2023
Inventors:
- Horsham PA, US
Shu Li - Dresher PA, US
Bruce Randazzo - Rydal PA, US
Kun Song - Collegeville PA, US
Yaowei Zhu - Chester Springs PA, US
International Classification:
C07K 16/24
A61P 17/06
Abstract:
Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.
